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bjectives This study compared health-related quality of life in patients undergoing carotid artery
tenting (CAS) versus surgical endarterectomy (CEA).
ackground Carotid artery stenting is approved in the U.S. for treating carotid stenosis in patients
t high surgical risk. Whether CAS offers advantages in terms of other patient-centered outcomes is
nknown.
ethods We evaluated health-related quality of life in the SAPPHIRE (Stenting and Angioplasty with
rotection in Patients at High Risk for Endarterectomy) trial, which randomized 334 high-risk
atients with carotid stenosis to CAS versus CEA. Health status assessments were obtained at base-
ine; 2 weeks; and 1, 6, and 12 months after revascularization. Generic measures included the Short-
orm-36 (SF-36) (0 to 100 scale), general health rating, and EuroQol (EQ-5D). In addition, we used 6
isease-speciﬁc modiﬁed Likert scales to assess difﬁculty with walking, eating/swallowing, driving,
eadaches, neck pain, and leg pain.
esults In patients treated according to protocol (n  159 CAS; n  151 CEA), CAS patients had
etter scores at 2 weeks for the SF-36 role physical scale (mean difference: 9.0; 95% conﬁdence in-
erval: 0.9 to 17.1; p  0.031), but these differences had resolved by 1-month follow-up. For the
isease-speciﬁc scales, CAS patients reported less difﬁculty eating/swallowing at 2 weeks, less difﬁ-
ulty driving at 2 weeks, and less neck pain at 2 weeks; each of these differences between groups
as no longer present at 1 month. No other scores differed between groups at any time point.
onclusions Among patients at high surgical risk, CAS was associated with less health status im-
airment during the ﬁrst 2 weeks of recovery when compared with CEA. However, these differences
ad resolved by 1 month after the procedure, and no other differences between revascularization
trategies in health-related quality of life were found. (J Am Coll Cardiol Intv 2010;3:515–23)
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516or decades, carotid endarterectomy (CEA) has been con-
idered the standard of care to prevent stroke in patients
ith severe atherosclerotic carotid stenosis (1–3). However,
any patients are considered poor candidates for CEA due
o medical comorbidities or advanced age, and these indi-
iduals experience higher rates of adverse outcomes (4).
arotid artery stenting (CAS) recently has been developed
s a less invasive option for revascularization and has been
valuated as an alternative strategy for patients at high risk
f adverse outcomes with surgical CEA. In the SAPPHIRE
Stenting and Angioplasty with Protection in Patients at
igh Risk for Endarterectomy) trial, the combination of
AS with an embolic protection device was demonstrated
o be noninferior to CEA for the prevention of death,
troke, or myocardial infarction among patients at high risk
f surgical complications (5). As a result of this study and
thers, CAS with embolic protection was approved by the
.S. Food and Drug Administration in 2004 for treatment
f both symptomatic and asymptomatic carotid artery ste-
osis in patients at high surgical risk.
However, subsequent evalua-
tions of CAS have yielded con-
flicting results, with some studies
demonstrating acceptable rates of
safety and efficacy (6–9) and oth-
ers finding worse outcomes in
lower-risk patients when com-
pared with CEA (10,11). In light
of this variability between studies,
other outcomes may better reflect
relevant strengths and weaknesses
of each revascularization strategy.
In particular, by virtue of its less
invasive nature, CAS may lead to
ore rapid functional recovery compared with CEA, as well as
mproved health-related quality of life (HRQOL) after the
rocedure. To assess these possible benefits, we performed a
rospective quality of life study as part of the SAPPHIRE trial.
ethods
rial design. Details of the SAPPHIRE trial design and
rimary clinical outcomes have been described previously
5). In brief, adult patients with symptomatic carotid artery
tenosis 50% or asymptomatic carotid stenosis 80%
ere eligible for enrollment at 29 centers if they were
onsidered to be at high risk for complications from surgical
EA. Patients were randomly assigned in a 1:1 ratio to
AS or CEA. Carotid endarterectomy was performed
ccording to standard techniques. Carotid artery stenting
sed a self-expanding nitinol stent (Smart or Precise,
ordis, Bridgewater, New Jersey) and an embolic protection
bbreviations
nd Acronyms
AS  carotid artery
tenting
EA  carotid
ndarterectomy
Q-5D  EuroQol
RQOL  health-related
uality of life
F-36  Medical Outcomes
tudy Short-Form 36evice (Angioguard or Angioguard XP, Cordis). Approval fas obtained from the Human Studies Committee at each
nrolling site.
atient population and clinical results. In SAPPHIRE, 334
atients were randomized (167 to each treatment group).
ight CAS patients and 16 CEA patients were not treated
s randomized due to deterioration of their clinical condi-
ion (3 CAS, 4 CEA), inability to meet the enrollment
riteria (2 CAS, 4 CEA), or withdrawal of consent prior to
reatment (3 CAS, 8 CEA). Because no HRQOL data were
ollected for patients who withdrew from the study, the
resent analysis compared quality of life in patients treated
ccording to protocol (n  159 receiving CAS, n  151
eceiving CEA). Subjects who died during the study were
ncluded in the analyses of HRQOL outcomes up until the
ime of death.
The clinical results of SAPPHIRE have been presented
reviously (5). In the overall trial, randomization to CAS
ith embolic protection was demonstrated to be noninferior
o CEA (intention-to-treat analysis) for reducing the pri-
ary clinical end point (composite of death, stroke, or
yocardial infarction within 30 days, and death or ipsilat-
ral stroke between 31 and 365 days). There was a strong
rend toward reduction of the primary end point with CAS
12.2% vs. 20.1%, p  0.053) and fewer repeat carotid
evascularizations at 1 year (0.6% vs. 4.3%, p  0.040).
easures of HRQOL. The HRQOL outcomes were assessed
t baseline, 2 weeks, and during additional follow-up visits
t 1, 6, and 12 months. These outcomes included 3 generic
RQOL measures and several disease-specific assessments.
The generic measures of health status evaluated in
APPHIRE included patient-reported ratings of general
ealth (0 to 100 scale, with higher score indicating better
unctioning), and 2 standardized measures of general health
tatus: the Medical Outcomes Study Short-Form 36 (SF-
6) (12) and the EuroQol (EQ-5D) (13). The SF-36 is a
ommonly used health survey that has been well validated in
atients with cardiovascular disease, stroke, and in the
eneral population (12,14–16). Only 4 of the 8 subscales of
he SF-36 (physical functioning, physical role limitations,
odily pain, and vitality) were used in this study as they were
xpected to be most sensitive to differences between CAS
nd CEA in the post-intervention period. Scores on these
cales range from 0 (worst) to 100 (best). The utility score
rom the EQ-5D incorporates 5 domains of health status
mobility, self-care, usual activities, pain/discomfort, anxi-
ty/depression) into a single value that reflects an individ-
al’s preference for his or her current health state relative to
erfect health (17,18). Scores range from 0 (equivalent to
eath) to 1 (best possible health status); the EQ-5D also has
een validated in multiple clinical scenarios including stroke
19–21).
In addition to these generic HRQOL instruments, 6
isease-specific modified Likert scales designed specifically
or SAPPHIRE were used to evaluate aspects of functional
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517tatus and symptoms that may be influenced by 1 or both of
he treatments. The first 3 questions assessed the level of
ifficulty each patient experienced with walking, eating/
wallowing, and driving (1  no difficulty at all, 2  mild
ifficulty, 3  moderate difficulty, 4  severe difficulty, 5 
nable to perform this activity). The last 3 questions
valuated how often patients were bothered by headaches,
eck pain, and leg pain during the previous week (1  not
t all bothered, 2  bothered a little bit, 3  moderately
othered, 4  bothered quite a bit, 5  extremely
othered).
tatistical analysis. Bivariate analysis of baseline character-
stics was performed using chi square for categorical, t test
or continuous, and appropriate nonparametric tests for
ariables without normal distribution. Follow-up health
tatus scores and changes in scores from baseline were
ompared between CAS and CEA groups using analysis of
ovariance for continuous variables and ordinal logistic
egression for categorical variables, adjusting for baseline
cores. Multiple imputation was used to estimate missing
RQOL scores for surviving patients. Covariates used in
he multiple imputation models included all of the available
RQOL scores, treatment assignment, and baseline clinical
nd demographic characteristics. Any p values 0.05 were
onsidered statistically significant, and no adjustments were
erformed for multiple comparisons. All analyses were per-
ormed using SAS software version 9.1 (SAS Institute, Cary,
orth Carolina).
esults
atient population and completeness of data. Baseline de-
ographic and clinical characteristics for the HRQOL
tudy population are summarized in Table 1. Mean age was
2 years, 68% were male, 26% had diabetes, and 86% had
ypertension. The CAS patients had higher rates of prior
oronary bypass surgery (43% vs. 32%, p  0.04) and prior
ercutaneous coronary intervention (34% vs. 23%, p 
.03), but all other baseline characteristics were similar
etween the 2 groups. Among surviving patients, overall
esponse rates were 80% at all time points with the
xception of 1-year follow-up, where response rates were
4% and 67% for the CAS and CEA groups, respectively
Fig. 1).
RQOL results. Results of the generic quality-of-life analy-
es (based on both raw and multiply imputed data) are
ummarized in Table 2. At baseline, each of the HRQOL
ubscales was well matched for the 2 groups. When com-
ared with subjects undergoing surgical revascularization,
AS patients reported better scores at 2 weeks for the
F-36 role physical scale (mean difference: 9.0, 95% confi-
ence interval: 0.9 to 17.1, p  0.031), but these differences
ere no longer apparent at 1-month follow-up. There were do significant differences for any of the other generic health
tatus scales between the CAS and CEA groups at 2 weeks
r at any other time points (Fig. 2). Findings were similar
hen multiple imputation was used to account for missing
ollow-up data.
Results of the disease-specific modified Likert scales are
ummarized in Figures 3 and 4. At 2 weeks, CAS patients
eported less difficulty eating or swallowing (Fig. 3A), less
ifficulty driving (Fig. 3C), and less neck pain (Fig. 4B).
owever, all of these differences had resolved by the
-month follow-up assessment. There were no significant
ifferences for any of the other disease-specific scales (dif-
culty walking, headaches, or leg pain) at 2 weeks or any
ther follow-up time point.
iscussion
lthough carotid stenting was developed more than 10
ears ago as a less invasive form of revascularization for
atients with carotid artery stenosis, to our knowledge no
revious studies have directly compared HRQOL and
ecovery patterns between CAS and CEA. In this prospec-
ively designed substudy of the SAPPHIRE trial, patients
reated with CAS experienced significant health status
enefits during the early recovery period relative to those
reated with surgical CEA. In particular, physical limita-
ions in role function (i.e., the ability to carry out one’s usual
ctivities) as well as difficulty with eating or swallowing,
Table 1. Baseline Characteristics of Patients Treated With CAS Versus
CEA in the SAPPHIRE Trial
CAS
(n  159)
CEA
(n  151) p Value
Demographics
Age, yrs 72 8 72 9 0.90
Male sex 68 68 0.94
Medical history
Diabetes mellitus 26 27 0.86
Hypertension 86 85 0.87
Current smoker 16 17 0.92
Prior myocardial infarction 30 35 0.36
Prior coronary bypass surgery 43 32 0.04
Prior percutaneous coronary
intervention
34 23 0.03
Heart failure 18 18 0.99
Chronic obstructive lung disease 18 13 0.21
Cerebrovascular history
Symptomatic carotid disease 30 28 0.74
Prior stroke 27 24 0.54
Prior CEA 29 24 0.31
Data are presented as mean SD or %.
CAS  carotid artery stenting; CEA  carotid endarterectomy; SAPPHIRE  Stenting and
Angioplasty with Protection in Patients at High Risk for Endarterectomy.ifficulty driving, and neck pain were less frequent among
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518atients undergoing CAS than among those undergoing
EA. The duration of any benefits were limited to the first
weeks of the post-operative period, however, and all other
easures of disease-specific health status as well as general
ealth and physical function were similar at 1, 6, and 12
Figure 1. Completeness of Data
Available health status data in patients treated according to protocol in the SA
ing patients with health status scores available at that time point. CAS  caro
Table 2. Baseline Generic Health Status Scores and Differences Between C
Health Status
Measure
Mean Baseline Scores ( SD)
CAS CEA 2 We
Raw data
Current health rating 69.2 19.5 68.8 19.0 1.3 (–4.1
SF-36 subscales
Physical limitations 53.0 29.5 51.6 29.6 1.9 (–3.9
Role physical 35.5 39.9 33.6 41.0 9.0 (0.9 t
Bodily pain 63.6 26.8 61.9 27.1 1.7 (–4.4
Vitality 50.2 22.5 47.9 23.2 3.3 (–2.0
EQ-5D utility score 0.73 0.22 0.72 0.20 0.01 (–0.0
Multiply imputed data
Current health rating — — 2.0 (–3.2
SF-36 subscales
Physical limitations — — 2.7 (–2.7
Role physical — — 8.8 (1.5 t
Bodily pain — — 3.3 (–2.6
Vitality — — 3.4 (–1.5
EQ-5D utility score — — 0.02 (–0.0
*p 0.05 for the comparison of CAS versus CEA.CI confidence interval; EQ-5D EuroQol utility score; SF-36Medical Outcomes Study Short-Form 3onths after carotid revascularization. Importantly, despite
he inclusion of a complex, elderly patient population with
high degree of comorbidity, there was no evidence of a
ignificant decline in physical function over the year of
ollow-up.
E trial. Percentages listed above each bar indicate the proportion of surviv-
ery stenting; CEA  carotid endarterectomy.
ersus CEA During Follow-Up
Mean Difference During Follow-Up (CAS-CEA) (95% CI)
1 Month 6 Months 12 Months
1.7 (–5.8 to 9.1) 2.6 (–5.8 to 11.0) 10.1 (–0.8 to 21.0)
7.9 (–1.7 to 17.4) –2.1 (–13.8 to 9.6) 7.7 (–4.2 to 19.6)
* 3.7 (–9.8 to 17.1) –1.3 (–20.3 to 17.7) 4.8 (–6.8 to 16.4)
1.6 (–7.4 to 10.5) 2.9 (–7.8 to 13.5) –7.0 (–19.3 to 5.4)
3.3 (–4.1 to 10.6) –4.2 (–12.6 to 4.2) 5.9 (–3.2 to 15.0)
6) 0.03 (–0.05 to 0.10) 0.01 (–0.07 to 0.10) 0.04 (–0.01 to 0.10)
0.4 (–3.9 to 4.7) 1.3 (–3.2 to 5.9) 3.3 (–1.8 to 8.4)
1.5 (–3.7 to 6.6) –1.4 (–7.2 to 4.4) 2.1 (–3.9 to 8.2)
* 4.0 (–8.7 to 16.7) –0.5 (–15.9 to 14.9) 6.2 (–9.7 to 22.1)
–2.7 (–8.1 to 2.7) 1.2 (–4.8 to 7.2) –2.6 (–9.2 to3.9)
–1.2 (–5.7 to 3.3) –4.2 (–8.9 to 0.4) 1.0 (–4.3 to 6.3)
7) –0.03 (–0.08 to 0.02) 0.01 (–0.04 to 0.05) 0.02 (–0.03 to 0.08)PPHIRAS V
eks
to 6.8)
to 7.6)
o 17.1)
to 7.9)
to 8.7)
4 to 0.0
to 7.2)
to 8.0)
o 16.2)
to 9.2)
to 8.4)
4 to 0.06; other abbreviations as in Table 1.
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519The early differences in health status recovery likely
eflect the less invasive nature of CAS versus CEA. This is
specially evident in the divergence of the modified Likert
cales related to discomfort near the carotid incision (neck
ain, pain with eating or swallowing). The finding that
AS patients had less difficulty with driving at 2 weeks was
omewhat surprising (we had anticipated the opposite
ffect) but may reflect delayed healing of the incision site
fter CEA. Alternatively, this difference in recovery may be
n artifact of post-operative instructions that often recom-
end avoidance of certain activities for several weeks.
Figure 2. Generic Health Status
Trend in scores for the generic health status measures, from baseline to 1 yea
0.05) were only noted at the 2-week follow-up visit for the SF-36: Role Physica
tions as in Figure 1.egardless of the mechanism for these differences, the sxtent of physical recovery was similar after either CAS or
EA beyond the first few weeks in this study.
omparison with prior studies. Multiple studies have as-
essed HRQOL after CEA, with varying results. For
xample, several single-center studies have reported no
ecrement in self-reported HRQOL at 6 months after
EA (22–24), results that were sustained at 8 to 11 years in
series (25). Other uncontrolled studies have reported
ignificant improvement in HRQOL after CEA (26,27),
nd at least 1 study described significant worsening of health
tatus after CEA (28). To date, only 1 nonrandomized
er scores indicate better quality of life; signiﬁcant differences in scores (p 
cale. EQ-5D  EuroQol utility score; SF-36  Short-Form 36; other abbrevia-r. High
l substudy has evaluated HRQOL after CAS versus CEA and
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520eported no significant differences between the 2 procedures
t 1 year (earlier time points were not assessed) (29). Our
nalysis from SAPPHIRE therefore provides unique insight
nto the short- and intermediate-term HRQOL benefits of
Figure 3. Disease-Specific Functional Limitations
Trend in scores from baseline to 1 year for (A) difﬁculty eating or swallow-
ing, (B) difﬁculty walking, and (C) difﬁculty driving. Abbreviations as in
Figure 1.AS relative to CEA and has the advantages of being perived from a head-to-head, randomized comparison. The
onger-term findings of our analysis are consistent with
rior studies demonstrating stabilization and convergence of
ealth status measures over time after both procedures.
Whereas HRQOL has been evaluated in numerous
tudies comparing different interventions for the treatment
f symptomatic vascular disease (e.g., medical vs. surgical vs.
Figure 4. Disease-Specific Pain Scales
Trend in scores from baseline to 1 year for (A) headaches, (B) neck pain,
and (C) leg pain. Abbreviations as in Figure 1.ercutaneous treatment for obstructive coronary artery dis-
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521ase or lower extremity claudication) (30–37), the objective
f this analysis was to compare the trajectory of recovery after
evascularization procedures for treatment of carotid artery
tenosis, which is often clinically silent. This is an important
istinction from studies that have compared the HRQOL
enefits of alternative treatments for symptomatic condi-
ions such as chronic stable angina and lower extremity
laudication, in which patients generally experience sub-
tantial symptom relief immediately after revascularization.
more analogous clinical condition is asymptomatic ab-
ominal aortic aneurysm, for which percutaneous versus
pen repair has been compared (38–41). These compari-
ons have generally demonstrated similar clinical outcomes
ut better patient-reported health status using the less
nvasive percutaneous options, as recovery is shorter and
ssociated with fewer complications. Moreover, studies of
ndovascular versus surgical treatment of abdominal aortic
neurysm have generally demonstrated comparable health
tatus at 1 year; these findings are similar to those for CAS
ersus CEA in our study.
linical implications. Our findings have several important
mplications for the choice of treatment for patients referred
or carotid revascularization. In particular, given the small
agnitude and limited duration of observed differences in
RQOL, these findings suggest that differences in patient
ecovery and overall QOL should play a relatively minor role
n deciding between the less invasive CAS approach and the
ore invasive CEA procedure. Nonetheless, the observed
ifferences in the early recovery period were both statistically
nd clinically important and may be sufficient to influence
atients’ decision making, as long as there is reasonable
onfidence that the risk of other serious adverse outcomes
oes not differ between the strategies. These findings are in
ontrast to the larger and more prolonged differences in
arly health status and recovery between percutaneous and
urgical coronary revascularization (30–33,42,43), which
ay even outweigh important differences in long-term
linical outcomes in the minds of many patients and
linicians (44). The results from SAPPHIRE suggest that
ifferences in other factors such as the risk of stroke,
yocardial infarction, or restenosis should be the most
mportant factors to consider when deciding between these
approaches to carotid revascularization. Consequently,
ngoing efforts to more clearly define the long-term benefits
f both procedures both in terms of stroke prevention as
ell as other complications are essential to providing the
vidence base for informed patient decision making.
tudy limitations. Several limitations should be acknowl-
dged before applying our findings to health policy or
linical practice. First, the SAPPHIRE trial only included
atients at high surgical risk; whether lower-risk patients
xperience smaller or larger differences in HRQOL (either
arly or late after revascularization) will require further studyn other populations. A second limitation is that our
n-treatment analysis cannot account for underlying biases
ith respect to who underwent treatment per protocol,
espite the randomized nature of the overall SAPPHIRE
rial. Furthermore, the exclusion of patients who died
uring follow-up could have biased our results toward the
ull hypothesis of no difference, if deaths were more likely
o occur among patients with the highest degree of comor-
idity and resulting physical impairments. Differences in the
vailability of follow-up health status data for survivors
etween the CAS and CEA groups may have also tended to
ias our results toward the null hypothesis, particularly at
he later time points where these differences were most
ronounced. In addition, the fact that SAPPHIRE patients
ere unblinded with respect to their assigned treatment may
ave introduced biases in subsequent responses to health
tatus assessments.
Finally, given the modest sample size (SAPPHIRE was
erminated early due to challenges in patient recruitment),
ur study may have been underpowered to detect modest
reatment effects at the later time points. For example, post
oc power calculations suggest that our study only had 68%
ower to detect a clinically important difference of 12 points
n the SF-36 role-physical scale at 1 month (45). Similarly,
ower to detect a 15% absolute reduction in the rate of any
imitation on the modified Likert scales at 1 month ranged
rom 69% to 88%. As a result, future studies evaluating
arotid revascularization may need substantially larger sam-
le sizes to identify clinically meaningful differences in
ealth status during the recovery phase after CAS versus
EA.
onclusions
n summary, among patients at high surgical risk, CAS was
ssociated with less health status impairment during recov-
ry (specifically physical role limitations and localized dis-
omfort) when compared with CEA. However, these dif-
erences were resolved by 1 month after the procedure, and
o other differences between revascularization strategies in
RQOL were found. These results, in conjunction with
vidence relating to the comparative risk of other key
linical outcomes (e.g., stroke, myocardial infarction, reste-
osis), should help to better inform patients regarding the
isks and benefits of alternative approaches to carotid
evascularization and lead to enhanced, patient-centered
ecision making.
eprint requests and correspondence:Dr. David J. Cohen, Saint
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